Rasagiline, 1 mg tab

Treatment of Parkinson’s disease (as monotherapy or combination therapy with L-DOPA's drugs)

Active ingredients

rasagilini mesilate 1,56 mg (conversion in rasagilin 1,00 mg);

Auxiliary ingredients

mannitol, amylum, pregelatinized starch, talc, magnium stearate.

Antiparkinsonian neurology

Treatment of Parkinson’s disease (as monotherapy or combination therapy with L-DOPA's drugs).

Is to be administered by mouth, with or without a meal, at a dose of 1 mg once per day, both in monotherapy and in combination with L-DOPA.

Dosage modification in elderly patients is not required.

The administration of rasagiline in patients with liver failure degree from moderate to severe is contraindicated.

Administering rasagiline in patients with mild hepatic insufficiency requires due caution. If progression of liver failure to a moderate degree is noted during the treatment with rasagiline, the use of the drug should be discontinued.

In patients with renal failure dosage moderation is not required.

Shelf life
3 years. Prohibited to use after expiry date.

Storage conditions
Store at a temperature below +25°С. Keep out of reach of children.

Terms of sale
RX only.

for adults and elderly people

starts acting in 30 min after intake

not more than 1 mg per day